Claret
Christophe Claret, Chez-Le-Bart CH
Patent application number | Description | Published |
---|---|---|
20140016445 | TIMEPIECE - A timepiece is equipped with a novel type of entertainment, that is a mechanical card game. The timepiece includes: a dial ( | 01-16-2014 |
Claude Claret, Nice FR
Patent application number | Description | Published |
---|---|---|
20130129844 | Preservative-Free Composition for Topical Use Including Hyaluronic Acid - The present invention relates to a sterile and/or decontaminated composition for topical use, including hyaluronic acid at a concentration of greater than or equal to 0.1 wt % relative to the total weight of the composition, at least one skin wound healing agent, optionally at least one plant extract, and at least one solvent. The invention also relates to a unit including such a composition, to a method for preparing such a composition, and to the uses thereof. | 05-23-2013 |
20130156867 | Artificial Tear Emulsion - The present invention relates to an oil-in-water emulsion comprising at least one mucomimetic polymer, at least one lipid of phospholipid type, at least one lipid other than the phospholipid, at least one stabilizing polymer, and a hydrophilic liquid, to an emulsion comprising an aqueous phase that contains at least one stabilizing polymer and at least one mucomimetic polymer, and an oily phase that contains at least one lipid of phospholipid type and a lipid other than the phospholipid, to a medicament comprising one of these emulsions, and to the use of one of these emulsions as an agent for restoring and/or replacing the lachrimal film or as a carrier for an active compound. | 06-20-2013 |
Emmanuel Claret, Besancon FR
Patent application number | Description | Published |
---|---|---|
20100210630 | Diamine Derivatives as Inhibitors of Leukotriene A4 Hydrolase - This invention is directed to compounds of formula (I): | 08-19-2010 |
20130123243 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE - This invention is directed to compounds of formula (I): | 05-16-2013 |
20150080382 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE - This invention is directed to compounds of formula (I): | 03-19-2015 |
Emmanuel Claret, Rochefort Du Gard FR
Patent application number | Description | Published |
---|---|---|
20100086943 | METHOD FOR THE DETECTION OF POST-TRANSLATIONAL MODIFICATIONS - Method for the detection in homogeneous medium of a post-translational modification of a protein substrate catalyzed by a cell enzyme, characterized in that the post-translational modification reaction takes place in intact living cells, in that these cells comprise a heterologous expression vector coding for a fusion protein comprising the protein substrate and a first coupling domain and in that it comprises the following stages: (v) Incubation of the cells in the presence or in the absence of a compound to be tested capable of modulating the activity of said enzyme, (vi) Addition to the reaction medium of a first fluorescent compound member of a first pair of FRET partners covalently bonded to a coupling agent capable of binding specifically to the first coupling domain present on the protein substrate, (vii) Addition to the reaction medium of a second fluorescent compound member of this first pair of FRET partners, and covalently bonded to a binding domain specific to the site of the protein substrate having undergone the post-translational modification and not binding to the non-modified protein substrate, (i) Measurement of the FRET signal emitted by the sample, this signal being representative of the quantity of protein substrate having undergone said post-translational modification; and cells for the implementation of said method. | 04-08-2010 |
20120009593 | ANALYSIS METHOD FOR THE IN VITRO DIAGNOSIS OF BENIGN PROSTATIC HYPERPLASIA (BPH) IN DOGS BY ASSAYING CANINE PROSTATE SPECIFIC ESTERASE, AND BPH TREATMENT FOLLOW UP - The invention relates to an analysis method for the in vitro diagnosis of benign prostatic hyperplasia (BPH) in a dog, using the CPSE contained in biological fluid samples collected from the dog as well as biological molecules specifically binding CPSE. The invention is characterised in that it includes the following steps: a. collecting a biological fluid sample from a dog; b. measuring the canine prostate specific esterase (CPSE) of said sample; c. comparing said measured CPSE concentration with a reference value, said value being from around 34 ng/ml to around 102.4 ng/ml for serum or plasma, preferably around 61 ng/ml; d. using the CPSE concentration as a BPH marker; and e. diagnosing BPH in a dog when measured CPSE concentrations in said sample exceed said reference value. | 01-12-2012 |
Francois Claret, Houston, TX US
Patent application number | Description | Published |
---|---|---|
20090148868 | JAB1 AS A PROGNOSTIC MARKER AND A THERAPEUTIC TARGET FOR HUMAN CANCER - Methods of diagnosing and prognosticating the development of human cancers, such as breast cancer, colon cancer, and pancreatic cancer, are provided. The diagnostic and prognostic methods include the detection and/or quantifying of the amount of expression of JAB1 in human cells, particularly in relation to the amount of p27 or c-Jun. In addition, methods for reducing the expression of JAB1 protein in cells and inhibiting its interaction with p27 or c-Jun, for example, are provided. | 06-11-2009 |
Jorge Blasco Claret, Valencia ES
Patent application number | Description | Published |
---|---|---|
20130147572 | POWER SUPPLY CABLE FOR POWER LINE COMMUNICATION EQUIPMENT - A method including receiving power, from a power line, at a device configured to communicate via the power line. The power from the power line is received at the device via a power cord of the device being connected, via a connector, to a power outlet from which the power of the power line is supplied. The connector is coupled to a first end of the power cord. The device is coupled to a second end of the power cord. The method further includes supplying a signal generated by the device to a choke located on the power cord. The choke is located closer to the first end of the power cord than to the second end of the power cord. The method further includes transmitting the signal from the choke to the power line for communication via the power line. | 06-13-2013 |
Julien Claret, Villefranche Sur Saone FR
Patent application number | Description | Published |
---|---|---|
20130078285 | IMPLANT FOR TISSUE REPAIR - Mono- and multi-layered implants include at least one porous layer made from a freeze dried aqueous solution containing chitosan, the solution having a pH of less than about 5. | 03-28-2013 |
Martine Claret, Nice FR
Patent application number | Description | Published |
---|---|---|
20130129844 | Preservative-Free Composition for Topical Use Including Hyaluronic Acid - The present invention relates to a sterile and/or decontaminated composition for topical use, including hyaluronic acid at a concentration of greater than or equal to 0.1 wt % relative to the total weight of the composition, at least one skin wound healing agent, optionally at least one plant extract, and at least one solvent. The invention also relates to a unit including such a composition, to a method for preparing such a composition, and to the uses thereof. | 05-23-2013 |
20130156867 | Artificial Tear Emulsion - The present invention relates to an oil-in-water emulsion comprising at least one mucomimetic polymer, at least one lipid of phospholipid type, at least one lipid other than the phospholipid, at least one stabilizing polymer, and a hydrophilic liquid, to an emulsion comprising an aqueous phase that contains at least one stabilizing polymer and at least one mucomimetic polymer, and an oily phase that contains at least one lipid of phospholipid type and a lipid other than the phospholipid, to a medicament comprising one of these emulsions, and to the use of one of these emulsions as an agent for restoring and/or replacing the lachrimal film or as a carrier for an active compound. | 06-20-2013 |